...colorectal cancer. Hood was director of research at TargeGen Inc., which originally developed fedratinib. Sanofi acquired TargeGen...
...Celgene Corp. (NASDAQ:CELG), Summit, N.J. Impact Biomedicines Inc., San Diego, Calif. Business: Hematology Jennie Walters fedratinib lenalidomide Revlimid Celgene Corp. Impact Biomedicines TargeGen Inc. JAK-2 Janus...

...colorectal cancer. Hood was director of research at TargeGen Inc., which originally developed fedratinib. Sanofi acquired TargeGen...

...return if all milestones are reached. Other investments include Medicago Inc. (Quebec City, Quebec) and TargeGen Inc....

...from FDA for the trial. The pharma gained the product through its 2010 acquisition of TargeGen Inc....

...of fedratinib outweighed its benefit. The pharma gained the product through its 2010 acquisition of TargeGen Inc....

...on a potential time frame. Sanofi, which gained the product through its 2010 acquisition of TargeGen Inc....

...pharma, which gained the selective oral Janus kinase-2 (JAK-2) inhibitor through its 2010 acquisition of TargeGen Inc....

...are available online .(A) From Genzyme acquisition; (B) Antisense therapy; (C) From 2010 acquisition of TargeGen Inc....

...two spectacular exits," Tilley said. The first came in 2010 when Sanofi (Euronext:SAN; NYSE:SNY) bought TargeGen Inc....
...could bring the return to 3X. This year, Sanofi will report Phase III data for TargeGen's...

...of Hematology meeting in Atlanta. Sanofi, which gained the product through its 2010 acquisition of TargeGen Inc....